Vigil Neuroscience, TREM2 and Alzheimer's Disease

Vigil Neuroscience Reports Positive Data from its Phase 1 Clinical Trial Evaluating VG-3927 for the Potential Treatment of Alzheimer’s Disease
Safety, tolerability, pharmacokinetic, and pharmacodynamic profile supports continued development of VG-3927 as potential once-daily oral therapy for Alzheimer’s disease (AD) - - Robust and dose-dependent reductions of sTREM2 were achieved demonstrating sustained functional target engagement – - Company plans to advance VG-3927 into a Phase 2 trial in the third quarter of 2025;
Analysts 'highly encouraged' by TREM2 reduction seen in Vigil's phase 1 Alzheimer's data
Vigil Neuroscience has reported early clinical data on its Alzheimer’s disease candidate, positioning the biotech to advance its small molecule in the footsteps of AbbVie and Alector’s failed rival antibody.
Promising Prospects for Vigil Neuroscience Inc. with VG-3927: A Groundbreaking Oral TREM2 Agonist
Analyst Andrew Fein from H.C. Wainwright maintained a Buy rating on Vigil Neuroscience Inc (VIGL – Research Report) and keeping the price
Vigil’s TREM2-Targeted Alzheimer’s Treatment Shows Early Promise, Moves on to Phase II
Vigil Neuroscience reported a strong safety profile and 50% sTREM2 reduction in an early-stage trial for VG-3927, potentially representing a new avenue for treating Alzheimer’s disease.
Vigil Neuroscience shares rise on positive Alzheimer's trial data
Shares of Vigil Neuroscience , Inc. (NASDAQ:VIGL) climbed 14% after the company reported favorable results from its Phase 1 clinical trial for VG-3927, a potential treatment for Alzheimer's disease (AD).
Vigil Neuroscience’s VG-3927: Promising Phase 1 Results and Strategic Positioning for Phase 2
Jason Butler, an analyst from JMP Securities, reiterated the Buy rating on Vigil Neuroscience Inc (VIGL – Research Report). The associated
Vigil Neuroscience gains after early-stage data for Alzheimer’s drug (update)
Shares of Vigil Neuroscience (NASDAQ:VIGL) rose ~18% in the premarket on Thursday after the Sanofi (SNY)-backed biotech said that it expects to advance its Alzheimer's candidate VG-3927 into a Phase 2 trial in Q3 2025 due to encouraging data the oral therapy generated in a Phase 1 trial.
Vigil Neuroscience advances Alzheimer's drug to Phase 2 trial
WATERTOWN, Mass. - Vigil Neuroscience , Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company, has announced the progression of its Alzheimer’s disease (AD) candidate, VG-3927, into a Phase 2 clinical trial slated for the third quarter of 2025.
Vigil Neuroscience: Now A 'Hold' Based On Two New Pipeline Developments
Vigil posted positive phase 1 results for VG-3927, but competitor Alector's failure raises concerns about phase 2. Click here ...
Vigil likely to land Alzheimer’s deal after today’s data, says Mizuho
Mizuho analyst Graig Suvannavejh says Vigil Neuroscience (VIGL) this morning reported positive top-line P1 data for VG-3927, a novel small ...
Nasdaq15d
Vigil Neuroscience Highlights 2024 Achievements and 2025 Milestones for Alzheimer’s and ALSP Treatments
Vigil Neuroscience, Inc. has announced its plans to report data from its Phase 1 clinical trial of VG-3927, a TREM2 agonist for Alzheimer’s disease, in the first quarter of 2025, and expects to ...
Vigil Neuroscience's Alzheimer's Candidate Shows Encouraging Safety Profile, Plans To Start Mid-Stage Study In Q3
Vigil Neuroscience Inc. (NASDAQ:VIGL) released data from its completed Phase 1 trial evaluating VG-3927 as a potential ...